Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It induces vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. It is available as standard tablets and orally disintegrating tablets (ODT). ## Primary Indications Acute treatment of migraine attacks with or without aura in adults and pediatric patients (aged 6–17 years). ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg. * **Administration:** If the migraine recurs after initial relief, a second dose may be taken after at least 2 hours. * **Maximum Dose:** 30 mg in a 24-hour period. * **ODT Formulation:** No water required; place on tongue and allow to dissolve; swallow with saliva. ## Pediatric Dosing * **Aged 6–17 years (Weight < 40 kg):** 5 mg single dose. * **Aged 6–17 years (Weight ≥ 40 kg):** 10 mg single dose. * **Maximum Dose:** Only one dose should be administered within a 24-hour period for pediatric patients. Safety and efficacy of a second dose have not been established in this population. ## Dose Adjustments * **Renal Impairment:** No specific adjustment required. * **Hepatic Impairment:** Mild to moderate impairment, no adjustment required, but use with caution. * **Patients taking Propranolol:** Use 5 mg dose (cumulative max 15 mg/24 hours) due to increased bioavailability of rizatriptan. ## Contraindications * History of ischemic heart disease (e.g., history of MI, angina, silent ischemia). * Coronary artery vasospasm (Prinzmetal’s angina). * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease. * Uncontrolled hypertension. * Hemiplegic or basilar migraine. * MAOI therapy (within 2 weeks of discontinuation). * Use within 24 hours of another 5-HT1 agonist or ergotamine-type medication. ## Adverse Effects * **Common:** Dizziness, somnolence, paresthesia, fatigue, nausea, dry mouth. * **Serious:** Coronary artery vasospasm, myocardial infarction, arrhythmias, life-threatening serotonin syndrome, cerebral hemorrhage. ## Key Drug Interactions * **MAOIs:** Significantly increase rizatriptan plasma levels; contraindicated. * **Propranolol:** Increases rizatriptan concentration by inhibiting metabolism. * **SSRIs/SNRIs:** Risk of serotonin syndrome when combined with triptans. * **Ergot-containing drugs:** Increased risk of prolonged vasospastic reactions; avoid within 24 hours. ## Monitoring * Monitor blood pressure periodically, especially in patients with cardiovascular risk factors. * Assess for chest pain, palpitations, or signs of ischemic cardiac/cerebrovascular events after the first dose. * Monitor for symptoms of serotonin syndrome (agitation, hallucinations, tachycardia, hyperreflexia). * Track frequency of use to avoid medication-overuse headache (limit use to <10 days per month). ## Clinical Pearls * **Efficacy:** Effectiveness is not affected by the presence of food, though ODT absorption may be slightly delayed. * **Delayed Treatment:** If a patient fails to respond to the first dose, the diagnosis of migraine should be reconsidered before administering a second dose for the same attack. * **Administration:** ODT blister packs should be handled with dry hands; the foil should be peeled back (not pushed through) to remove the tablet. * **Uncertainty Note:** Specific institutional protocols regarding pediatric dosing thresholds or comorbidities may vary slightly from manufacturer labeling; always consult local pediatric clinical pathways. *** **Educational Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, package inserts, and hospital-specific guidelines before administering or prescribing medication.